Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
As a result, GLP-1 therapies are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
PLoS One 8 (4), e61965
Aggressive treatment of all risk factors for macrovascular disease (smoking cessation, ASA for procoagulant state, treatment of dyslipidemia, hypertension and obesity)
Patients don't just feel full - they also experience uncomfortable bloating and swollen bellies
Book an appointment with us today or call us at 888-559-9205 to get personalized care.
Key Highlights Three once-monthly injections achieved placebo-adjusted weight loss of up to 6.3% at Week 12, increasing to 7.5% at Week 16 Weight loss maintained up to 4 months after the final dose, supporting once-quarterly maintenance therapy potential No weekly lead-in dosing required, differentiating ASC30 from many current GLP-1 regimens Safety profile consistent with the GLP-1 class, with mild-to-moderate adverse events and no discontinuations Why It Matters: Convenience advantage: Monthly or quarterly dosing could significantly improve adherence vs weekly GLP-1 injections Small-molecule innovation: ASC30 is a GLP-1 biased small molecule, enabling both oral and injectable formulations Platform validation: Supports Ascletis Ultra-Long-Acting Platform (ULAP) for developing long-duration metabolic therapies Key Takeaway: ASC30 highlights the next frontier in obesity therapeuticsultra-long-acting incretin therapies
